777pub taya
Cloud Infrastructure Entitlement Management Market Growing Trends, Business Growth, Size, Future Scope, Segmentation, Dynamics and Forecast to 2028Macron names ally Bayrou as new PM as he aims to restore political stability
WOBURN, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it has submitted a biologics license application (BLA) to the FDA for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of adult patients with advanced melanoma who have previously received an anti-PD1 containing regimen. The submission was made under the Accelerated Approval pathway. The Company also announced that the FDA has granted Breakthrough Therapy designation to RP1 in combination with nivolumab in the same setting. Breakthrough Therapy designation is intended to expedite the development and review of therapies for serious diseases when preliminary clinical evidence indicates that the therapy may provide substantial improvement over existing available therapies on one or more clinically significant endpoints. This Breakthrough Therapy designation is based on the safety and clinical activity observed in the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial. “Today is an important milestone for Replimune and for the melanoma community as we are one step closer to having another potential treatment available for patients who have limited options after progressing on anti-PD1 containing regimens,” said Sushil Patel, Ph.D., CEO of Replimune. The confirmatory Phase 3 IGNYTE-3 trial of RP1 in combination with nivolumab in advanced melanoma patients who have progressed on anti-PD1 and anti-CTLA-4 therapy, or who are not candidates for anti-CTLA-4 treatment is currently enrolling patients. For more information, visit https://replimune.com/clinical-trials/ignyte-3/ . About RP1 RP1 (vusolimogene oderparepvec) is Replimune’s lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF, intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com . Forward Looking Statements This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our belief regarding the effect that the breakthrough designation will have on the timing and development of RP1 and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to generate positive clinical trial results for our product candidates, the costs and timing of operating our in-house manufacturing facility, the timing and scope of regulatory approvals, the availability of combination therapies needed to conduct our clinical trials, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, political and global macro factors including the impact of the coronavirus as a global pandemic and related public health issues and the Russian-Ukrainian and Israel-Hamas political and military conflicts, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements. Investor Inquiries Chris Brinzey ICR Healthcare 339.970.2843 chris.brinzey@westwicke.com Media Inquiries Arleen Goldenberg Replimune 917.548.1582 media@replimune.comA high-profile barrister who was cleared of misconduct over social media posts has called on the head of the Bar Standards Board to resign. Dr Charlotte Proudman, who specialises in family law, had faced a Bar Standards Board (BSB) disciplinary tribunal over a 14-part Twitter thread criticising a judge’s ruling over a domestic abuse case, saying it echoed a “boys’ club”. However, the five charges against the 36-year-old were dropped on Thursday. In an interview with The Times, Dr Proudman described the position of Mark Neale, the board’s director-general, as “untenable” and said its chairwoman, Kathryn Stone, should also stand down. “They need a change, not just in those two individuals, though, because, of course, it seeps down to the rest of the organisation,” she said. She told the paper she “genuinely” wanted to work with the Bar Standards Board in helping them to understand how misogyny and sexism have impacted women at the bar. However, she said that “under the current leadership, it’s just not going to be possible”. The charges alleged Dr Proudman had “failed to act with integrity” in posting the tweets, that they amounted to professional misconduct, were “misleading” and “inaccurately reflected the findings of the judge” in the case. The women’s rights campaigner was also accused of behaving in a way “which was likely to diminish the trust and confidence which the public placed in her and in the profession”, and that she “knowingly or recklessly misled or attempted to mislead the public” by making the posts. But panel chairman Nicholas Ainley found her tweets are protected under Article 10 of the Human Rights Act 1998 and the European Convention on Human Rights, which protects the right of freedom of expression. He said her tweets did not “gravely damage” the judiciary, which would “put them outside” of Article 10 protection, even if they “might not have been pleasant for any judge to read” or even “hurtful”. “We take the view that the judiciary of England and Wales is far more robust than that,” he said. The panel also concluded that some of the tweets were only inaccurate “to a minor degree” and not to the extent necessary for a charge of a lack of integrity. Speaking after the hearing, Dr Proudman told the PA news agency: “This ruling is a victory for women’s rights and a right to freedom of speech. “The prosecution against me brought by my regulatory body, the Bar Standards Board, should never have happened and I said that from day one. “I criticised a domestic abuse judgment. Everyone should have the right to do that, whether you’re a barrister or not. Our justice system, which I strongly believe in, is robust enough to withstand criticism from me.” She believes her tweets help “foster confidence” in the justice system, adding: “Only that way can we go about building change and a better treatment for all victims, women and children and men who are affected by domestic abuse.” Explaining that the BSB appears to have spent almost £40,000 “of barristers’ money” on instructing counsel in her case, she added: “I think it’s shameful that they’re using our money to pay for, in my view, malicious, vexatious prosecutions which I have no doubt was a personal attack against me as a woman and as a feminist, as an outspoken critic and advocate for women’s rights.” Dr Proudman called for “systemic change” within the board. “They don’t understand gender, they don’t understand diversity, I don’t think they’ve ever heard of the concept misogyny and certainly not institutional misogyny,” she said. “Until they recognise the deeply rooted, entrenched issue of bullying, harassment, sexism at the bar, for which I have suffered relentlessly... and own up to it I don’t think we’re going to see any change and I have no confidence in them.” She told of how male barristers have called her insulting names on social media and made derogatory comments about her. In the posts on April 6 2022, Dr Proudman referenced a case in which her client alleged she had been subjected to coercive and controlling behaviour by her husband, a part-time judge, meaning she had been “unable to freely enter” the couple’s “post-nuptial” financial agreement. Commenting on the ruling by Family Court judge Sir Jonathan Cohen, Dr Proudman wrote: “I represented Amanda Traharne. “She said she was coerced into signing a post-nuptial agreement by her husband (who is a part-time judge). I lost the case. “I do not accept the Judge’s reasoning. I will never accept the minimisation of domestic abuse.” She continued: “Demeaning the significance of domestic abuse has the affect of silencing victims and rendering perpetrators invisible. “This judgement has echoes of (t)he ‘boys club’ which still exists among men in powerful positions.” In the thread, Dr Proudman wrote that the judge had described the relationship of the couple as “tempestuous”, which she argued was a “trivialisation” of domestic abuse. “Tempestuous? Lose his temper? Isn’t this the trivialisation of domestic abuse & gendered language. This is not normal married life,” she wrote.
Agriculture & Natural Solutions Acquisition Corporation Receives FIRB Approval In Connection with Previously Announced Business Combination
HSFTOOLS Expands the Thermal Imaging Market with a Focus on Practical ApplicationsMalcolm In the Middle's Frankie Muniz details hair loss battle and how finding the solution got him 'back into racing' Have YOU got a story? Email tips@dailymail.com By DAILYMAIL REPORTER Published: 23:15, 13 December 2024 | Updated: 23:30, 13 December 2024 e-mail 2 View comments Malcolm In the Middle star Frankie Muniz opened up about his hair loss journey, how balding affected his confidence and finally finding a solution with his wife's help. Over the years, the actor, 39, admitted that he tried a variety of treatments, including a hair transplant, but ended up suffering from some rare side effects, which left him disheartened. While appearing on HairClub's podcast, HairPod , the father-of-one, admitted that he struggled with accepting his hair thinning in his early twenties as someone who always had 'thick hair' growing up. In an effort to slow down his hair loss, he 'started taking medications and doing topical creams and [wearing] laser hats.' 'I remember it just kind of continued to get worse and worse and worse,' he recalled. 'I really didn't know what to do, almost to the point to where I kind of gave up on it.' Ultimately, Muniz said he 'was tired of trying things that weren't helping the situation' and it made him 'more and more self conscious' about his hair. Malcolm In the Middle star Frankie Muniz opened up about his hair loss journey, how balding affected his confidence and finally finding a solution with his wife's help; seen in 2023 At the time, he remembered hyperfixating on his hair whenever he passed a mirror and was always 'talking pictures' and 'comparing' it to past photographs. Muniz recalled first struggling with hair loss while filming the last season of his hit series, Malcolm In the Middle, which aired from 2000 to 2006. Read More Malcolm In the Middle's Frankie Muniz details hair loss battle and how finding the solution got him 'back into racing' It also coincided to his pivot to racing cars professionally. 'I don't want to say it shocked me how I went from having hair to not having hair,' he began. 'I didn't really notice it, like, until I noticed it.' After wrapping Malcolm In the Middle, Muniz said, without the assistance of hair and makeup styling him, he finally noticed his hair loss. 'I started having to actually comb my hair for the first time myself,' he said, referring to the time period after Malcolm In the Middle ended. 'It definitely was just a shock, you know, especially because I was young, 19 or 20 years old.' Despite being in the spotlight and having a team of people working for him, the actor said he was on his own navigating his hair loss. 'I didn't have anybody helping me,' he said, before detailing his trial and errors, before finding the hair restoration company, HairClub. Over the years, the actor, 39, admitted that he tried a variety of treatments, including a hair transplant, but ended up suffering from some rare side effects, which left him disheartened While appearing on HairClub's podcast, HairPod , the father-of-one, admitted that he struggled with accepting his hair thinning in his early twenties as someone who always had 'thick hair' growing up While discussing his openness about his hair loss, Muniz admitted that others in his industry are 'afraid' to talk about what treatments they've done to fix it. 'I think it's interesting because, you know, we live, especially now, in a time where most celebrities, most people that you see on social media have tons of work and they don't hide it, but it's still a touchy subject when it comes to men talking about their hair,' he pointed out. He continued: 'I think that's an interesting thing because, like, it's not something that you can help, right? If you're losing your hair, if you have issues like that, it's nothing like you did something wrong or, you know, what I mean? It's genetics.' Muniz noted that it was his wife, Paige Price, who forced him to do a hair consultation with HairClub when he had resorted to just wearing hats and shaving his head. In response to his hair loss, he 'started taking medications and doing topical creams and [wearing] laser hats' in an effort to slow down the balding process 'I remember it just kind of continued to get worse and worse and worse,' he recalled. 'I really didn't know what to do, almost to the point to where I kind of gave up on it' 'I was so used to being kind of let down by the results of things that you spent a lot of money on, or you spent a lot of time or pain, like, physical pain. So I kind of didn't have very high hopes,' he remembered. After working with HairClub, however, he said he received 'immediate gratification' and a boost to his confidence. 'It was truly life changing,' he said of his results. 'It changed every aspect of my life. It made me more confident in everything from a work standpoint, from a working out standpoint, everything!' Following his hair transformation, which he described as basically immediate, the performer said it gave him the 'confidence' to get back to racing. 'I think I'd kind of just kind of crawled almost in a hole a little bit,' he confessed. 'And kind of just stayed away from the acting stuff, stayed away from kind of like putting myself out there... I hate to admit that almost, but I didn't realize it had such a big effect on me in a negative way.' After working with HairClub, however, he said he received 'immediate gratification' and a boost to his confidence; seen on February 17, 2024 Following his hair transformation, which he described as basically immediate, the performer said it gave him the 'confidence' to get back to racing Frankie was just a teenager when he rocketed to fame as the star of the hit sitcom, Malcolm In The Middle. The series also starred Bryan Cranston, who would later become a household name for his role in Breaking Bad. The young actor was nominated for Best Performance by an Actor in a TV-Series Comedy/Musical for his role, but lost to Charlie Sheen for Spin City. Frankie remained in the spotlight following his run on Malcolm In The Middle, with roles in several Sharknado films and even a hosting stint on Dancing With The Stars: Junior. Next, he is set to return to the Malcolm in the Middle reboot, which will stream on Disney+ and Hulu. Share or comment on this article: Malcolm In the Middle's Frankie Muniz details hair loss battle and how finding the solution got him 'back into racing' e-mail Add comment
Home Oxygen Machines: Revolutionizing At-Home Health Care for Respiratory Patients and Improving Quality of LifeIn its recently released blueprint, Info-Tech Research Group is providing insurers with a comprehensive framework to tackle the growing challenges of data privacy in the age of AI. In the resource, the global research and advisory firm recommends AI training, strong data governance, and proactive risk management to help insurers safeguard personally identifiable information (PII) while using AI for underwriting, claims processing, and customer engagement. TORONTO , Dec. 13, 2024 /PRNewswire/ - As AI adoption continues to accelerate, the insurance industry is under increasing pressure to safeguard personally identifiable information (PII) against sophisticated data privacy risks. Global research and advisory firm Info-Tech Research Group explains in a newly published industry resource that traditional system safeguards and outdated legacy systems are proving insufficient to address the complexities of modern AI-driven processes, leaving insurers exposed to regulatory and technological vulnerabilities. To help insurers tackle these pressing challenges, Info-Tech Research Group's blueprint, Safeguard Your Data When Deploying AI in Your Insurance Systems , offers a strategic framework for integrating privacy-preserving AI solutions. The firm's resource features research insights and tools that will equip IT leaders in the insurance sector to strengthen compliance, mitigate risks, and protect PII while maintaining system performance. "Insurers handle vast amounts of data, from health records to financial histories, fed into AI systems that promise accuracy and efficiency but pose privacy concerns," says Arzoo Wadhvaniya , research analyst at Info-Tech Research Group . "A single breach could compromise thousands of customers' personal information, causing severe reputational and financial damage. It is not just about what AI can do; it is about ensuring it is done securely and ethically." In the blueprint, Info-Tech explains that traditional data safeguarding methods in the insurance industry are increasingly ineffective, as legacy systems often lack the flexibility to meet modern demands. The firm's research findings suggest that unfamiliarity with integrated AI technologies can lead to confusion among employees when assessing risks and determining appropriate applications. Complex regulatory requirements, which may not align with AI-driven processes, further heighten compliance challenges. To address these issues, Info-Tech recommends AI training programs to help employees understand associated risks and foster a culture of security and compliance. "Regulatory frameworks demand strict compliance, yet AI introduces complexities that make this harder. Insurers must ensure AI respects customer consent, limits data usage, and mitigates bias. Otherwise, the consequences could be costly in terms of both fines and lost trust," explains Wadhvaniya . Info-Tech's new resource provides IT leaders in the insurance industry with actionable strategies to address critical risks associated with generative AI. The firm emphasizes the importance of identifying insurance-specific risks and adopting a continuous improvement approach supported by metrics and a risk-based strategy aligned with a privacy framework tailored to organizational needs. The research highlights three key risks tied to generative AI: The firm advises the industry to take a proactive stance, implementing robust data governance practices, ensuring transparency, and fostering customer trust in the responsible use of AI. By leveraging insights from this blueprint, insurance companies can effectively address growing data privacy challenges while adopting advanced AI technologies for underwriting, claims processing, and customer engagement. For exclusive and timely commentary from Arzoo Wadhvaniya, an expert in IT strategies, and access to the complete Safeguard Your Data When Deploying AI in Your Insurance Systems blueprint , please contact pr@infotech.com . About Info-Tech Research Group Info-Tech Research Group is one of the world's leading research and advisory firms, proudly serving over 30,000 IT and HR professionals. The company produces unbiased, highly relevant research and provides advisory services to help leaders make strategic, timely, and well-informed decisions. For nearly 30 years, Info-Tech has partnered closely with teams to provide them with everything they need, from actionable tools to analyst guidance, ensuring they deliver measurable results for their organizations. To learn more about Info-Tech's divisions, visit McLean & Company for HR research and advisory services and SoftwareReviews for software buying insights. Media professionals can register for unrestricted access to research across IT, HR, and software and hundreds of industry analysts through the firm's Media Insiders program. To gain access, contact pr@infotech.com . For information about Info-Tech Research Group or to access the latest research, visit infotech.com and connect via LinkedIn and X . View original content to download multimedia: https://www.prnewswire.com/news-releases/insurers-urged-to-safeguard-data-amid-rising-ai-adoption-and-privacy-risks-says-info-tech-research-group-302331530.html SOURCE Info-Tech Research Group
Until now, Ms Weinstein has been the US firm’s vice president and managing director in the UK and Ireland, having previously worked at Unilever. She said her focus will be on “unlocking AI-powered growth for everyone”, calling the current AI boom a “pivotal” time for the tech giant. Google has joined many of its rivals in launching a string of high-profile generative AI products in recent times, led by the firm’s generative AI-powered assistant, Gemini. “Europe, the Middle East and Africa is an amazingly diverse and varied region, but the enormous growth opportunity that AI can create is universal,” she said. “My focus will be on unlocking that AI-powered growth for everyone – users, businesses, partners and governments across every part of the region. “I’m excited to be stepping into this role at a pivotal time, in a company where I’ve spent the last ten years and leading a region where I’ve spent much of my life.” Google employs more than 29,000 people across Europe, the Middle East and Africa, with 56 offices across 35 countries in those regions working on many of the firm’s largest products, including its search engine, the Android mobile operating system and its Chrome web browser. Its AI research arm, at Google DeepMind, is also led from London. Philipp Schindler, Google senior vice president and chief business officer, said: “This is the AI era and we are only just beginning to see its transformative impact on business and society. “In such a pivotal moment for technology, I’m thrilled we’ve appointed a visionary leader to be our President of Google EMEA. “Debbie brings a track record of unlocking growth that benefits everyone, alongside the passion and focus needed to help our customers succeed, as we bring the best of Google’s Gemini-era to everyone across EMEA.”
SAN JOSE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Credo Technology Group Holding Ltd (Nasdaq: CRDO), an innovator in providing secure, high-speed connectivity solutions that deliver improved energy efficiency as data rates and corresponding bandwidth requirements increase through the data infrastructure market, today reported financial results for the second quarter of fiscal year 2025, ended November 2, 2024. Second Quarter of Fiscal Year 2025 Financial Highlights Management Commentary Bill Brennan, Credo’s President and Chief Executive Officer, stated, “In the fiscal second quarter ended November 2, 2024 Credo generated record revenue of $72.0 million, up 21% sequentially and 64% year over year. The second quarter was our most successful to date across our three main product lines and Credo delivered total product revenue of $69.1 million. For the past few quarters, we have anticipated an inflection point in our revenues during the second half of fiscal 2025. I am pleased to share that this turning point has arrived, and we are experiencing even greater demand than initially projected, driven by AI deployments and deepening customer relationships.” Third Quarter of Fiscal 2025 Financial Outlook Conference Call Credo will conduct a conference call on Monday, December 2, 2024, at 2:00 p.m. Pacific Time to discuss its financial results for the second quarter of fiscal year 2025, ended November 2, 2024. Interested parties may join the conference call by registering online at https://register.vevent.com/register/BI87c69953bb554b49af7cc32591eee82a . After registering, a confirmation will be sent through email, including dial-in details and a unique conference call code for entry. It is recommended that participants register and dial in for the call at least 10 minutes before the start of the call. A live webcast of the conference call will be available on Credo’s Investor Relations website at http://investors.credosemi.com . A replay of the webcast will be available via the web at http://investors.credosemi.com . Discussion of Non-GAAP Financial Measures This press release contains references to the non-GAAP financial measures of non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP operating income (loss), non-GAAP operating income (loss) margin, non-GAAP net income (loss) and non-GAAP diluted net income (loss) per share. Reconciliation of these non-GAAP measures to their comparable GAAP measures is included below. This non-GAAP information should not be construed as an alternative to the reported results determined in accordance with GAAP. The non-GAAP financial measures that Credo presents may not be comparable to similarly titled measures of other companies and other companies may not calculate such measures in the same manner as we do. Non-GAAP financial measures exclude the effect of share-based compensation expenses, asset impairment and related charges (if applicable), and the related tax effect adjustment to the provision for income taxes. Credo uses a full-year non-GAAP tax rate to compute the non-GAAP tax provision. This full-year non-GAAP tax rate is based on Credo’s annual GAAP income, adjusted to exclude non-GAAP items, as well as the effects of significant non-recurring and period-specific tax items which vary in size and frequency. Credo’s non-GAAP tax rate is determined on an annual basis and may be adjusted during the year to take into account events that may materially affect the non-GAAP tax rate, such as tax law changes, significant changes in Credo’s geographic mix of revenue and expenses or changes to Credo’s corporate structure. GAAP diluted net income (loss) per share is calculated using basic weighted average shares outstanding when there is a GAAP net loss, and calculated using diluted weighted average shares outstanding when there is a GAAP net income. Non-GAAP diluted net income (loss) per share is calculated using basic weighted average shares outstanding when there is a non-GAAP net loss, and calculated using non-GAAP diluted weighted average shares outstanding when there is a non-GAAP net income. Non-GAAP adjustment for the number of shares used in the diluted per share calculations excludes the impact of share-based compensation expenses expected to be incurred in future periods and not yet recognized in the financial statements, which would otherwise be assumed to be used to repurchase shares under the GAAP treasury stock method. Credo believes that the presentation of non-GAAP financial measures provides important supplemental information to management and investors regarding financial and business trends relating to Credo’s financial condition and results of operations. While Credo uses non-GAAP financial measures as a tool to enhance its understanding of certain aspects of its financial performance, Credo does not consider these measures to be a substitute for, or superior to, financial measures calculated in accordance with GAAP. Consistent with this approach, Credo believes that disclosing non-GAAP financial measures to the readers of its financial statements provides such readers with useful supplemental data that, while not a substitute for GAAP financial measures, allows for greater transparency in the review of its financial and operational performance. Externally, management believes that investors may find Credo’s non-GAAP financial measures useful in their assessment of Credo's operating performance and the valuation of Credo. Internally, Credo's non-GAAP financial measures are used in the following areas: Non-GAAP financial measures have limitations in that they do not reflect all of the costs associated with the operations of Credo’s business as determined in accordance with GAAP. As a result, you should not consider these measures in isolation or as a substitute for analysis of Credo’s results as reported under GAAP. The exclusion of the above items from our GAAP financial metrics does not necessarily mean that these costs are unusual or infrequent. Forward-Looking Statements under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact could be deemed forward-looking statements, including, but not limited to, any statements regarding: launches of new or expansion of existing products or services; technology developments and innovation; our plans, strategies or objectives with respect to future operations; financial outlook; future financial results; expectations regarding the markets and industries in which Credo conducts business; and assumptions underlying any of the foregoing. Words such as “anticipates,” “expects,” “intends,” “plans,” “projects,” “believes,” “seeks,” “estimates,” “can,” “may,” “will,” “would,” “outlook,” “forecast,” “targets” and similar expressions, or their negatives, may identify such forward-looking statements. These statements are not guarantees of results and should not be considered as an indication of future activity or future performance. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that may cause actual events or results to differ materially from those described in this press release. Readers are encouraged to review risk factors and all other disclosures appearing in Credo’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission (SEC) on June 24, 2024, as well as Credo’s other filings with the SEC, for further information on risks and uncertainties that could affect Credo’s business, financial condition and results of operation. Copies of these filings are available from the SEC, Credo’s website or Credo’s investor relations department. Forward-looking statements speak only as of the date they are made. Credo assumes no obligation to update or revise any forward-looking statements as a result of new information, future events or otherwise, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date herein. About Credo Our mission is to deliver high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. Credo is an innovator in providing secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. Our innovations ease system bandwidth bottlenecks while simultaneously improving on power, security and reliability. Our connectivity solutions are optimized for optical and electrical Ethernet applications, including the 100G (or Gigabits per second), 200G, 400G, 800G and emerging 1.6T (or Terabits per second) port markets. Our products are based on our proprietary Serializer/Deserializer (SerDes) and Digital Signal Processor (DSP) technologies. Our product families include integrated circuits (ICs), Active Electrical Cables (AECs) and SerDes Chiplets. Our intellectual property (IP) solutions consist primarily of SerDes IP licensing. Investor Relations Contact: Dan O’Neil IR@credosemi.comMr Bayrou, 73, a crucial partner in Macron’s centrist alliance, has been a well-known figure in French politics for decades. His political experience is seen as key in efforts to restore stability as no single party holds a majority at the National Assembly. Mr Macron’s office said in a statement that Mr Bayrou “has been charged with forming a new government”. During the handover ceremony, Mr Bayrou said that “no one knows the difficulty of the situation better” than he does. “I’ve taken reckless risks all along my political life to raise the issue of debt and deficits in the most important elections,” he said. France is under pressure from the European Union’s executive body and financial markets to reduce its colossal debt, estimated to reach 6% of its gross domestic product this year. “I know that the risks of difficulties are much greater than the chances of success,” Mr Bayrou said, adding that he hopes to lead the country towards a “needed reconciliation”. “I think this is the only possible path to success,” he said. The new prime minister is expected to hold talks with political leaders from various parties in the coming days in order to choose new ministers. Former prime minister Michel Barnier resigned last week following a no-confidence vote prompted by budget disputes in the National Assembly, leaving France without a functioning government. Mr Macron in an address to the nation vowed to remain in office until his term ends in 2027. Mr Macron’s centrist alliance does not have a majority in parliament and Mr Bayrou’s Cabinet will need to rely on moderate lawmakers from the left and the right to be able to stay in power. Some conservatives are expected to be part of the new government. Mr Macron’s strategy aims at preventing far-right leader Marine Le Pen from holding “make or break” power over the government. Ms Le Pen helped oust Mr Barnier by joining her National Rally party’s forces to the left to pass the no-confidence motion last week. Mr Bayrou’s appointment is also in line with Mr Macron’s efforts to build a non-aggression pact with the Socialists so that they commit not to vote against the government in any future confidence motion. Mr Bayrou leads the centrist Democratic Movement, known as MoDem, which he founded in 2007. In 2017, he supported Mr Macron’s first presidential bid and became a weighty partner in the French president’s centrist alliance. At the time, he was appointed justice minister, but he quickly resigned from the government amid an investigation into the MoDem’s alleged embezzlement of European Parliament funds. Mr Bayrou this year was cleared in the case by a Paris court, which found eight other party officials guilty and sentenced the party to pay a fine. Mr Bayrou became well known to the French public when he was education minister from 1993 to 1997 in a conservative government. He was three times a candidate for president: in 2002, 2007 and 2012.